{
  "docId": "019de076-7d6c-774e-85e8-ffe50da37251",
  "docSlug": "0b0d701714d17efa78c23c196990e90c",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 37,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide highlights the strategic partnership and the division of commercial rights between Genelux and Newsoara.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7d6c-774e-85e8-ffe50da37251/20",
  "deckHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251",
  "deckJsonHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251.json",
  "deckAnchorHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.225
      },
      "kind": "list",
      "text": "Newsoara will fund the US-based Genelux Phase 2 trial in NSCLC. Newsoara has development and commercialization rights in Greater China. Systemic Trial Milestones: Initiate Phase 2 NSCLC: 1H, 2024; Phase 1b SCLC readout: 2H, 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e00252c-4d80-473e-9286-0c85129a803d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.4,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Genelux will have worldwide commercial rights (excluding Greater China) to all data generated from clinical trials of Olvi-Vec in China.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "250129e0-e67f-4329-bdec-787a5dc2a033",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.55,
        "x": 0.36,
        "y": 0.25
      },
      "kind": "table",
      "text": "Sponsor, Trial Sites, Indication, Clinical Stage, Patients (est.), Randomization, Status. US, Adjuvant Maintenance NSCLC, Phase II, ~142, 1:1, Regulatory Submission. China, Recurrent SCLC, Phase I/II, ~150, Single Arm, Enrolling. Recurrent OC, Phase I/II, ~150, 2:1, Regulatory Submission. Recurrent NSCLC, Phase I/II, ~150, 2:1, Planned",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1b37047-4f53-4fa7-a6bc-6091125d4cd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Validating Industry Collaboration with Newsoara BioPharma Co., Ltd",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e992564-836e-44a5-95d4-7e5d63c4365f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "708c92e4-10fb-4aa5-8568-a5ce81b333bf",
      "evidence": "table/data: Sponsor, Trial Sites, Indication, Clinical Stage, Patients (est.), Randomization, Status.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}